tradingkey.logo

Veracyte Inc

VCYT
43.150USD
+0.800+1.89%
Horário de mercado ETCotações atrasadas em 15 min
3.41BValor de mercado
112.49P/L TTM

Mais detalhes de Veracyte Inc Empresa

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.

Informações de Veracyte Inc

Código da empresaVCYT
Nome da EmpresaVeracyte Inc
Data de listagemOct 30, 2013
CEOMr. Marc A. Stapley
Número de funcionários824
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 30
Endereço6000 Shoreline Court, Suite 300
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94080
Telefone16502436300
Sitehttps://www.veracyte.com/
Código da empresaVCYT
Data de listagemOct 30, 2013
CEOMr. Marc A. Stapley

Executivos da empresa Veracyte Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
100.93K
-13.37%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
50.97K
-18.37%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
32.81K
+39.68%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
27.84K
+20.48%
Mr. Jens Holstein
Mr. Jens Holstein
Independent Director
Independent Director
25.73K
+56.82%
Ms. Rebecca Chambers
Ms. Rebecca Chambers
Chief Financial Officer
Chief Financial Officer
20.97K
-25.03%
Mr. Evan Jones
Mr. Evan Jones
Independent Director
Independent Director
19.00K
-40.99%
Mr. John Leite, Ph.D.
Mr. John Leite, Ph.D.
Global Chief Commercial Officer
Global Chief Commercial Officer
2.81K
-67.00%
Ms. Annie Mcguire
Ms. Annie Mcguire
Chief Human Resources Officer, General Counsel
Chief Human Resources Officer, General Counsel
2.24K
-49.11%
Ms. Karin Eastham, CPA
Ms. Karin Eastham, CPA
Independent Director
Independent Director
2.08K
-82.30%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
100.93K
-13.37%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
50.97K
-18.37%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
32.81K
+39.68%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
27.84K
+20.48%
Mr. Jens Holstein
Mr. Jens Holstein
Independent Director
Independent Director
25.73K
+56.82%
Ms. Rebecca Chambers
Ms. Rebecca Chambers
Chief Financial Officer
Chief Financial Officer
20.97K
-25.03%

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2024
FY2023
FY2022
FY2021
FY2020
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
423.54M
95.01%
International
22.23M
4.99%
Por Empresa
Por Região
Sem dados

Distribuição de ações

Atualizado em: qua, 8 de out
Atualizado em: qua, 8 de out
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.74%
Fidelity Management & Research Company LLC
8.77%
Artisan Partners Limited Partnership
8.00%
BlackRock Institutional Trust Company, N.A.
7.75%
ARK Investment Management LLC
5.65%
Outro
59.10%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.74%
Fidelity Management & Research Company LLC
8.77%
Artisan Partners Limited Partnership
8.00%
BlackRock Institutional Trust Company, N.A.
7.75%
ARK Investment Management LLC
5.65%
Outro
59.10%
Tipos de investidores
Investidores
Proporção
Investment Advisor
63.38%
Investment Advisor/Hedge Fund
34.71%
Hedge Fund
7.02%
Research Firm
2.77%
Pension Fund
1.91%
Individual Investor
0.53%
Bank and Trust
0.47%
Sovereign Wealth Fund
0.06%
Insurance Company
0.04%

Participação acionária institucional

Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
616
87.37M
110.53%
-1.45M
2025Q2
598
84.22M
107.53%
-1.90M
2025Q1
612
85.86M
109.67%
-679.43K
2024Q4
593
81.64M
104.75%
-2.62M
2024Q3
567
81.88M
106.62%
-2.30M
2024Q2
533
81.65M
106.83%
-3.86M
2024Q1
532
81.30M
103.75%
+1.22M
2023Q4
524
76.49M
104.40%
-3.87M
2023Q3
520
77.05M
105.90%
-3.78M
2023Q2
516
77.28M
106.70%
-4.52M
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
8.08M
10.27%
-163.29K
-1.98%
Jun 30, 2025
Fidelity Management & Research Company LLC
6.93M
8.81%
+761.45K
+12.34%
Jun 30, 2025
Artisan Partners Limited Partnership
6.32M
8.04%
+1.08M
+20.65%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.12M
7.78%
-81.10K
-1.31%
Jun 30, 2025
ARK Investment Management LLC
3.80M
4.83%
+594.86K
+18.56%
Jun 30, 2025
Wellington Management Company, LLP
3.47M
4.42%
-379.35K
-9.85%
Jun 30, 2025
State Street Investment Management (US)
3.17M
4.03%
+11.46K
+0.36%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
3.02M
3.84%
+111.60K
+3.83%
Jun 30, 2025
ArrowMark Colorado Holdings, LLC
2.58M
3.28%
-647.85K
-20.08%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.93M
2.46%
-3.46K
-0.18%
Jun 30, 2025
Ver Mais

ETFs Relacionados

Atualizado em: qui, 6 de nov
Atualizado em: qui, 6 de nov
Nome
Proporção
First Trust NYSE Arca Biotechnology Index Fund
3.94%
ARK Genomic Revolution ETF
3.42%
Invesco Biotechnology & Genome ETF
3.16%
Global X Genomics & Biotechnology ETF
3.07%
WisdomTree BioRevolution Fund
1.93%
Invesco S&P SmallCap Health Care ETF
1.72%
ROBO Global Healthcare Technology & Innovation ETF
1.61%
ROBO Global Artificial Intelligence ETF
1.53%
ARK Innovation ETF
1.46%
Invesco S&P SmallCap 600 Pure Growth ETF
1.39%
Ver Mais
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.94%
ARK Genomic Revolution ETF
Proporção3.42%
Invesco Biotechnology & Genome ETF
Proporção3.16%
Global X Genomics & Biotechnology ETF
Proporção3.07%
WisdomTree BioRevolution Fund
Proporção1.93%
Invesco S&P SmallCap Health Care ETF
Proporção1.72%
ROBO Global Healthcare Technology & Innovation ETF
Proporção1.61%
ROBO Global Artificial Intelligence ETF
Proporção1.53%
ARK Innovation ETF
Proporção1.46%
Invesco S&P SmallCap 600 Pure Growth ETF
Proporção1.39%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
KeyAI